CAR T SIM

AI-Driven CAR-T Treatment Strategies for Hematologic Neoplasms Simulation An experiment to push the envelope of AI: to explore whether an interdisciplinary AI Agents can work as a coordinated team to manage a highly complex environment in a clinical setting. Chimeric Antigen Receptor T-cell (CAR-T) therapy is a relatively recent treatment developed to fight certain blood cancers, such as leukemia and lymphoma. CAR-T therapy begins by collecting white blood cells called T cells from the patient. These cells are then genetically engineered to recognize and bind to cancer cells. The modified cells are expanded into the millions in the laboratory and infused back into the patient, where they seek out and destroy cancer cells with near-sniper precision. Metaphorically, you enter enemy territory, recruit ordinary citizens, train them into elite assassins, and send them back to eliminate enemy soldiers — a feat of medical ingenuity straight out of a spy thriller, evoking Carrie Mathison, Jack Bauer, and even a hint of Walter White. However, CAR-T therapy can trigger the release of cytokines in the patient’s body. Excessive cytokine release can be life-threatening, while too few CAR-T cells may allow the cancer to continue proliferating. Determining the correct dose is therefore a delicate balancing act. In this experiment, AI agents are tasked with administering and controlling CAR-T infusion to maximize cancer cell elimination while minimizing cytokine release. A mathematical model of a fed-batch chemical reactor is mapped onto patient physiology. The pumping of the heart represents the impeller; the vascular and lymphatic systems act as a well-mixed reactor; dose-dependent binding between CAR-T and cancer cells represents reaction kinetics; and changes in body temperature reflect the heat transfer and thermodynamics of these reactions. Blood pressure determines hemodynamics, which in turn govern fluid-mechanical properties such as shear stress. This shear stress influences the effective binding constant between CAR-T cells and cancer cells, with higher blood pressure reducing binding efficacy. Disclaimers: This is a hypothetical model to test the limits of AI Agents without considering evidence based findings. Demo of binding constants is based on previously published data for Gleevec-BCR-ABL binding. In conclusions, while AI agents — and AI as a whole—are not yet ready for this feat, they have demonstrated enormous potential.